PrimeGen to Go Public via $1.5B SPAC News: Nasdaq Listing Expected in H2 2026

Biotechnology company PrimeGen US has confirmed plans to enter public markets through a $1.5 billion merger with blank check company DT Cloud Star Acquisition, marking the latest SPAC news in the biotech sector. The combined entity will operate as PrimeGen US and trade on the Nasdaq Stock Exchange, with the transaction anticipated to close during the second half of 2026. This move reflects a broader industry shift, as more companies explore SPAC mergers as a viable alternative to traditional initial public offerings.

The SPAC Deal Structure and Timeline

The SPAC transaction represents a streamlined pathway to public listing. Rather than pursuing a conventional IPO, PrimeGen has opted to merge with DT Cloud Star Acquisition, a special purpose acquisition company that functions as a shell vehicle designed specifically to facilitate such transactions. These SPAC structures typically raise capital through their own public offerings before identifying and merging with target companies. With the deal expected to finalize in the latter half of 2026, PrimeGen will gain immediate access to public capital markets and the liquidity advantages that come with being a publicly traded entity on Nasdaq.

Biotech Innovation: Stem Cell Therapies and Market Opportunity

PrimeGen specializes in developing innovative stem cell therapies, with initial focus on treating acute liver injury and related critical illnesses. This therapeutic focus positions the company within a high-potential segment of biotechnology, where regenerative medicine continues to attract significant research investment and clinical interest. The company’s research pipeline addresses significant unmet medical needs, which could represent a meaningful market opportunity as regulatory pathways for stem cell-based treatments continue to mature globally.

Why SPACs Are Gaining Traction in Biotech

The renewed interest in SPAC mergers reflects how the biotech industry views this fundraising mechanism. Compared to traditional IPOs, SPAC transactions often provide more predictable timelines, reduced regulatory uncertainty, and streamlined capital access. For companies like PrimeGen, this SPAC news signals confidence in their commercial potential while offering an efficient route to public markets. As more biotechnology companies pursue this path, SPACs have evolved from a niche strategy into a mainstream financing mechanism for the sector.